Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2024
0mins
Should l Buy ?
Source: Globenewswire
Bionomics Limited Re-domiciliation: The Supreme Court of New South Wales has approved Bionomics Limited's scheme to re-domicile from Australia to the U.S., with Neuphoria Therapeutics Inc. becoming its parent company, effective December 23, 2024.
Trading Information: Bionomics' American Depositary Shares (ADSs) will continue trading on Nasdaq until the implementation date, and shares of Neuphoria are expected to begin trading under the symbol "NEUP" on December 24, 2024.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
